|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Incidence and duration of recurrence of respiratory tuberculosis in adults 显示文摘 | Gavrilenko VS Tavolzhanskii VP Oksachenko OO Miller VA Kozlova MK Spevak Ⅳ | 1993 | Probl Tuberk1993，，2： | 1 |
| 2 | Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer显示文摘 | Miller VA Kris MG Shah N | 2004 | J Clin Oncol2004，22，6： | 1 |
| 3 | Afatinib versus placebo for patients with advanced ,metastatic non-small- cell lung cancer after failure of erlotinib,gefitinib,or both,and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 显示文摘 | Miller VA Hirsh V Cadranel J | 2012 | Lancet Oncol2012，13，5： | 1 |
| 4 | Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions显示文摘 | PAO W MILLER VA | 2005 | J Clin Oncol2005，23，11： | 1 |
| 5 | Formation of austenite during intercritical annealing of dual-phase steels 显示文摘 | Speich Gr Demarest Va Miller RI | 1981 | Metallurgical Transactions1981，12，： | 1 |
| 6 | Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain显示文摘 | Pao W Miller VA Politi KA | 2005 | PLoS Med2005，2，3： | 1 |
| 7 | Phase Ⅱ trial of docetaxeland vinorelbine in-patients with advanced non-small cell lung cancer显示文摘 | Miller VA Krug LM Ng KK | 2000 | J Clin Onco12000，18，6： | 1 |
| 8 | Cyclooxygenase - 2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P - glycoprotein) 显示文摘 | Miller B Patel VA Sorokin A | 2006 | J Am Soc Nephrol2006，17，4： | 1 |
| 9 | Vascular endothelial growth factor trap in non - small cell lung cancer 显示文摘 | Riely GJ Miller VA | 2007 | Clin Cancer Res2007，13，15： | 1 |
| 10 | Bronchioloalveolar pathologic subtype and smoking histology predict sensitivity to gefitibnib in advanced non-small-cell lung cancer显示文摘 | Miller VA Kris MG Shah N | 2004 | J Clin Oncol2004，22，6： | 1 |
| 11 | Phase Ⅱ trial of a 75mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small-cell lung cancer显示文摘 | Miller VA Rigas JR Francis PA | 1995 | Cancer1995，75，4： | 1 |
| 12 | Intraosseous infusion:An alternative route of pediatric intravascular access显示文摘 | Rosetti VA Thompson BM Miller J | 1985 | Ann Emerg Med1985，14，9： | 1 |
| 13 | Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients : results of an online tumor registry of clinical trials显示文摘 | Jackman DM Miller VA Cioffredi LA | 2009 | Clin Cancer Res2009，15，16： | 1 |
| 14 | Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer 显示文摘 | Miller VA Kris MG Shah N | 2004 | J Clin Oncol2004，22，6： | 1 |
| 15 | Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib 显示文摘 | Miller VA Riely GJ Zakowski MF | 2008 | J Clin Oncol2008，26，9： | 1 |
| 16 | Intraosseous infu- sion:an alternative route of pediatric intravascular access显示文摘 | Rosetti VA Thompson BM Miller J | 1985 | Ann Emerg Med1985，14，9： | 1 |
| 17 | Molecular eharacteristies of hronehioloalveolar carcinmna and adenocarcinoma, bronchioloalve- olar carcinomasubtype, predict response to erlotinib 显示文摘 | Miller VA Riely GJ Zakowski MF | 2008 | J Clin Oncol2008，26，9： | 1 |
| 18 | Epidermal growth factor receptor mutations,small molecule kinase inhibitors,and non-small-cell lung cancer: current knowledge and future directions 显示文摘 | Pao W Miller VA | 2005 | J Clin Oncol2005，23，11： | 1 |
| 19 | Phase Ⅱ trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer显示文摘 | Miller VA Krug LM Ng KK | 2000 | J Clin Oncol2000，18，6： | 1 |
| 20 | Afatinib versus placebo far patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefiinib, or both, and one or two lines of chemo- therapy ( LUX-Lung 1 ) : a phase 2b/3 randomised trial显示文摘 | Miller VA Hirsh V Cadranel J | 2012 | Lancet Onco12012，13，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员